Oncovita has entered into a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform.   The licensed technology is based on changes in the measles viral genome designed to dramatically increase its anti-tumor properties. The viral genomics and vaccination unit of Institut Pasteur, Paris, France has previously successfully developed and patented other genetically...